Mirum Pharmaceuticals 2024年第四季度GAAP每股收益$(0.49)不及预期$(0.28),销售额为9943万美元,超出预期9660.6万美元

财报速递02-27
Mirum Pharmaceuticals (NASDAQ:MIRM)报告季度每股亏损$(0.49),比分析师的预期$(0.28)低75%。与去年同期每股亏损$(0.66)相比,同比减少25.76%。公司报告季度销售额为9943万美元,超出分析师预期的9660.6万美元,超出2.92%。这较去年同期的销售额6955.4万美元增长了42.95%。

以上内容来自Benzinga Earnings专栏,原文如下:

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.28) by 75 percent. This is a 25.76 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $99.430 million which beat the analyst consensus estimate of $96.606 million by 2.92 percent. This is a 42.95 percent increase over sales of $69.554 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法